BioHedge Weekly
13D/13G filings from 18 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform — clinical trials, SEC filings, and hedge fund positioning, linked by company.
Weekly Filing Volume
Filings This Week
| Company | Fund | Ownership | Type |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | Perceptive Advisors | 12.9% ↓2.7 | 13D/A [SEC] |
| SAB BIOTHERAPEUTICS INC (SABS) | RA Capital Management | 9.9% | 13D/A [SEC] |
| Solid Biosciences Inc. (SLDB) | RA Capital Management | 9.9% | 13D/A [SEC] |
Multi-Fund Activity
Companies with filings from multiple institutional investors this week.
| Company | Funds | Net Change |
|---|---|---|
| Solid Biosciences Inc. (SLDB) | 2 | -2.7% |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses >5% ownership in a company for the first time.
We track 18 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.